Prostate cancer, often developing insidiously over many years, poses a unique challenge. While many men live with indolent forms requiring minimal intervention, a subset faces aggressive variants that recur even after surgical removal of the tumor. Differentiating these phenotypes early has remained elusive, primarily due to an incomplete understanding of the molecular drivers governing tumor progression and recurrence. The NTNU research team addressed this by analyzing carefully preserved prostate tissue samples extracted from patients with well-documented clinical outcomes, some spanning retrospective follow-up periods exceeding a decade.

The cornerstone of this insight was identifying a unique gene expression signature inherent to the aggressive prostate tumors themselves. By mapping transcriptomic data onto spatial tissue architecture, the team delineated specific gene activation patterns predictive of recurrence and metastatic potential. This molecular fingerprint offers a promising biomarker panel that clinicians could employ to distinguish patients necessitating intensive therapy from those with more indolent disease courses, thereby enabling precision medicine in prostate cancer management.

Beyond the tumor margins, the normal-appearing adjacent prostate tissue exhibited profound metabolic and immunologic alterations, underscoring the concept that cancer’s influence pervades the surrounding microenvironment. Intriguingly, these benign regions manifested signs of chronic inflammation characterized by elevated neurotransmitters that attract immune effector cells and an increased presence of inflammatory cell subtypes capable of perpetuating immune reactions. Concurrently, essential metabolic compounds showed significant depletion, reflecting a loss of physiological glandular function — a hallmark of disrupted homeostasis in cancer proximate tissues.

This inflammatory milieu adjacent to the tumor may not simply be a bystander effect but could actively foster tumor progression and resistance to therapy. The study hypothesizes that the crosstalk between malignant cells and the inflamed stroma creates a niche conducive to cancer aggressiveness. Such findings add a new dimension to the current understanding of prostate cancer pathophysiology and open avenues for therapies targeting the microenvironment to prevent disease escalation.

Clinically, prostate cancer screening predominantly relies on digital rectal examinations and serum prostate-specific antigen (PSA) levels. While PSA testing has markedly increased early detection rates, this method falls short in stratifying risks accurately, leading to overtreatment in many cases, a concern given potential side effects like incontinence, erectile dysfunction, and psychological distress. NTNU’s novel findings pave the way for more nuanced diagnostic tools that could potentially reduce unnecessary interventions by pinpointing aggressive cancers with higher precision.

The research utilized human prostate tissue samples collected meticulously and analyzed retrospectively, emphasizing the laborious nature of longitudinal cancer research where outcomes like relapse may take nearly a decade to manifest. This persistence highlights the dedication essential for translating biological markers into clinically actionable data, underscoring the value of biobanking and long-term patient follow-up in oncological studies.

Advanced imaging with MRI remains a cornerstone in prostate cancer evaluation, offering detailed anatomical visualization. However, it lacks the molecular detail revealed by multi-omic profiling. The integration of molecular data with imaging could revolutionize prostate cancer diagnostics, shifting from solely structural assessments to comprehensive molecular characterizations, enabling earlier and more accurate identification of tumors likely to recur or metastasize.

At the forefront of this research, Sebastian Krossa notes the challenges in patient compliance with traditional exams and envisages a future where non-invasive screening through blood or sperm samples could be feasible. Such advancements would drastically lower barriers to detection and allow for timely interventions without discomfort or stigma associated with current sampling methods.

The importance of preventing overtreatment is a focal point in this research narrative. By better characterizing the aggressive subset of prostate cancers, clinicians can avoid the pitfalls of blanket treatment approaches and instead tailor interventions, thus preserving quality of life for patients with less severe disease. Reducing unnecessary therapy-related morbidity remains a critical challenge in oncology, and this study provides a vital piece to that puzzle.

The application of spatially resolved multi-omics represents a paradigm shift — moving from bulk tissue analyses toward decoding the intricate heterogeneity within tumors and adjacent tissues. This three-dimensional mapping grants unprecedented insights into cellular interactions and metabolic networks within the tumor microenvironment, a frontier that promises to redefine cancer biology.

Funded by the European Research Council’s Starting Grant, the NTNU team’s work exemplifies how foundational basic science research fuels clinical innovation. The integration of transcriptomic and metabolomic profiling with histopathological context yields comprehensive snapshots of cancer complexity, essential for healing advancements that extend beyond current standards of care.

In sum, these discoveries not only deepen scientific understanding of prostate cancer aggressiveness but also herald the development of next-generation diagnostic assays and personalized medicine strategies. The convergence of spatial biology, immunology, and metabolomics underscores a multifaceted attack on prostate cancer, equipping the medical community with tools to better predict, monitor, and treat this common yet heterogeneous disease.

Subject of Research: Human tissue samples

Article Title: Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment

News Publication Date: 19-Nov-2025

Web References:
http://dx.doi.org/10.1038/s41467-025-65161-9

References:
Krossa, S., Andersen, M.K., Sandholm, E.M. et al. Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment. Nat Commun 16, 10160 (2025).

Image Credits:
Photo: Anne Sliper Midling / NTNU

Keywords: Prostate cancer, aggressive tumor signature, spatial multi-omics, transcriptomics, metabolomics, tumor microenvironment, inflammation, biomarkers, cancer recurrence, personalized medicine

The test at the heart of this breakthrough, known as the Decipher Prostate Genomic Classifier, is an advanced molecular diagnostic tool that evaluates patterns of gene expression across a wide spectrum of cancer-related genes. By deciphering the tumor’s transcriptome, this test categorizes tumors into distinct risk profiles that correlate with treatment sensitivity and overall prognosis. While this test has been widely utilized in the United States for localized prostate cancer to predict the likelihood of progression, this study represents the first compelling evidence from a randomized clinical trial that it can also guide treatment decisions in patients whose cancer has spread beyond the prostate itself.

Central to the research was data from the STAMPEDE trial, a landmark phase III randomized controlled study that enrolled over 1,500 men diagnosed with advanced prostate cancer. These participants were treated with androgen deprivation therapy (ADT), which is designed to suppress male hormones like testosterone that fuel cancer growth. The STAMPEDE trial subsequently tested the addition of multiple therapies, including abiraterone and docetaxel chemotherapy, examining their ability to improve survival outcomes over a median follow-up period of 14 years. The depth and duration of this trial allowed the research team to undertake a comprehensive molecular analysis, correlating gene expression profiles with long-term clinical outcomes.

Crucially, the researchers focused on a subgroup of 832 patients with metastatic prostate cancer. Analysis revealed a striking divergence in survival benefits linked to the Decipher Prostate scores. Patients with high Decipher scores exhibited a remarkable 36% reduction in risk of death after receiving docetaxel chemotherapy, a benefit starkly contrasted with those exhibiting low scores who saw less than a 4% risk reduction. This differential response underscores the value of molecular profiling as a precision medicine approach, enabling oncologists to tailor treatments based on the intrinsic biology of each patient’s tumor rather than a one-size-fits-all strategy.

Chemotherapy with docetaxel, while capable of prolonging survival, often comes at the expense of patients’ quality of life due to significant side effects such as fatigue, neuropathy, and immunosuppression. Therefore, the ability to pre-identify patients unlikely to benefit spares them from unnecessary toxicity and offers clinicians the option to explore alternative therapies or supportive strategies. This represents a seminal advancement in the treatment paradigm for metastatic prostate cancer, where prediction and personalization have long been elusive.

The collaboration between UCL and Veracyte was essential to making this test accessible and validated in a clinical context. UCL’s expertise in cancer biology and clinical trial design paired with Veracyte’s capabilities in high-throughput gene expression profiling drove this innovation from concept to commercial availability. Moreover, beyond the Decipher test, the collaborative effort uncovered several novel molecular classifiers that have predictive value for patient outcomes and therapeutic responses, suggesting a broader landscape for future biomarker-driven treatment adjustments.

Further molecular insights emerged from the identification of a signature indicating inactivity in the tumor suppressor gene PTEN, a gene well-known for its role in regulating cell growth and survival. This PTEN inactivity signature was associated with both shorter survival when treated with hormone therapy alone and a greater benefit from chemotherapy. This dual predictive capacity sharpens the precision with which clinicians can stratify patients, emphasizing the intricate molecular interplay underpinning prostate cancer progression and treatment responsiveness.

Leading the scientific endeavor, Professor Gert Attard of UCL expressed optimism about the future impact of these findings. The integration of molecular profiling into clinical decision-making heralds a new era where chemotherapy can be individualized, improving outcomes and minimizing harm. This approach promises to revolutionize care and aligns with the broader trend in oncology towards treatment personalization driven by genomic insights rather than solely clinical staging or histopathology.

The significance of this advancement is further highlighted by epidemiological data: prostate cancer accounts for approximately 55,100 new cases annually in the UK, and it remains the second leading cause of cancer death among men, with 12,000 fatalities projected in the current year alone. Most deaths arise from cases initially diagnosed at advanced or metastatic stages, underlining the urgent need for refined therapeutic strategies tailored to individual tumor biology. The Decipher Prostate test, therefore, offers a real-world, clinically actionable tool to improve survival and quality of life on a large scale.

Prostate Cancer UK, Cancer Research UK, and several charitable foundations played key roles in funding this research, enabling the extensive clinical and molecular analyses required for such a landmark study. The STAMPEDE trial itself, a beacon of innovation in prostate cancer research, continues to foster discoveries that translate into improved standards of care for men with advanced disease states, fulfilling its mission to identify new, more effective therapies.

Dr. Emily Grist of the UCL Cancer Institute emphasized that this research represents a milestone in the molecular reclassification of prostate cancer. By dissecting tumors into distinct transcriptional subtypes predictive of treatment response, the study moves the field towards bespoke therapeutic regimens. Future clinical paradigms may involve biopsies routinely subjected to transcriptomic profiling, followed by matched treatment pathways that can dynamically evolve with emerging molecular data, ensuring patients receive the most effective and least harmful therapies available.

From a commercial and translational perspective, UCL Business (UCLB) has facilitated the transfer of these scientific insights into market-ready diagnostics. Their collaboration with Veracyte exemplifies how academic discoveries can be harnessed to yield real-world impact. The availability of the Decipher Prostate test in the US as a reimbursed clinical assay stands as a testament to the successful bridging of fundamental research and patient care, setting a blueprint for future biomarker-driven precision oncology.

In conclusion, the integration of transcriptome-wide molecular classifiers into therapeutic decision-making for advanced prostate cancer represents a transformative leap forward. This approach enables the identification of patients likely to derive meaningful survival benefits from docetaxel chemotherapy while sparing others from unnecessary toxicity. As further molecular signatures and classifiers are elucidated, including those involving PTEN inactivity, the future of prostate cancer treatment promises to be increasingly personalized, precise, and effective, embodying the modern principles of precision medicine.

Subject of Research: People

Article Title: Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

News Publication Date: 27-Aug-2025

Web References:

• Veracyte Official Website
• LinkedIn – Veracyte
• X (Twitter) – Veracyte

References:
10.1016/j.cell.2025.07.042 (DOI link to the publication in Cell)

Keywords: Prostate tumors, Molecular profiling, Advanced prostate cancer, Gene expression, Chemotherapy sensitivity, Decipher Prostate Genomic Classifier, STAMPEDE trial, Personalized medicine